biote (BTMD) 주식 개요
는 호르몬 최적화 분야의 실무 구축 비즈니스를 운영하고 있습니다. 자세히 보기
BTMD Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pharmaceuticals & Biotech opportunity
biote Corp. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$2.18 |
| 52주 최고가 | US$4.75 |
| 52주 최저가 | US$1.27 |
| 베타 | 1.71 |
| 1개월 변동 | 37.11% |
| 3개월 변동 | -1.36% |
| 1년 변동 | -45.36% |
| 3년 변동 | -61.95% |
| 5년 변동 | -78.10% |
| IPO 이후 변동 | -78.31% |
최근 뉴스 및 업데이트
내러티브 업데이트 • May 02
BTMD: Recall Disruption And Higher Investment Spend Will Set Up Later Upside
Narrative Update Analysts have trimmed the average price target for biote by about $0.20 as they factor in a lower fair value estimate, a higher assumed future P/E, and recent research pointing to recall related pressures, increased investment plans, and mixed clinic growth trends. Analyst Commentary Recent research updates on biote point to a mixed setup, with analysts weighing near term recall and investment headwinds against execution on sales initiatives and clinic growth potential.
내러티브 업데이트 • Apr 17
BTMD: Recall Resolution And Clinic Productivity Investments Will Support Future Upside
The average analyst price target on biote has been reduced to about $4 from roughly $6, as analysts factor in lower forecast revenue growth, slimmer projected profit margins, a higher discount rate, and a much higher assumed future P/E multiple following recent guidance updates and the impacts of the product recall. Analyst Commentary Recent Street research reflects a reset in expectations, but it also highlights areas where bullish analysts still see room for value creation if biote executes on its plans and manages the recall process effectively.내러티브 업데이트 • Apr 03
BTMD: Affordable Medicines Theme Will Support Upside As Investments Settle
Analysts have trimmed biote's average price target as firms reset expectations to a lower range of $2 to $5, citing the impact of a voluntary recall, higher operating investments, and slower clinic growth, even as they acknowledge progress on sales execution and systems upgrades. Analyst Commentary Recent research highlights a reset in expectations around biote, with lower price targets reflecting near term operational and growth headwinds, alongside recognition of execution progress and investments aimed at future expansion.
내러티브 업데이트 • Mar 20
BTMD: Affordable Medicines Theme Will Support Upside As 2026 Plan Advances
Analysts have trimmed the consolidated price target for biote to a range of about $2 to $3. This reflects more cautious assumptions on growth and profitability following guidance tied to the voluntary recall, higher investment, and slower clinic expansion.Recent updates
내러티브 업데이트 • May 02
BTMD: Recall Disruption And Higher Investment Spend Will Set Up Later Upside
Narrative Update Analysts have trimmed the average price target for biote by about $0.20 as they factor in a lower fair value estimate, a higher assumed future P/E, and recent research pointing to recall related pressures, increased investment plans, and mixed clinic growth trends. Analyst Commentary Recent research updates on biote point to a mixed setup, with analysts weighing near term recall and investment headwinds against execution on sales initiatives and clinic growth potential.내러티브 업데이트 • Apr 17
BTMD: Recall Resolution And Clinic Productivity Investments Will Support Future Upside
The average analyst price target on biote has been reduced to about $4 from roughly $6, as analysts factor in lower forecast revenue growth, slimmer projected profit margins, a higher discount rate, and a much higher assumed future P/E multiple following recent guidance updates and the impacts of the product recall. Analyst Commentary Recent Street research reflects a reset in expectations, but it also highlights areas where bullish analysts still see room for value creation if biote executes on its plans and manages the recall process effectively.내러티브 업데이트 • Apr 03
BTMD: Affordable Medicines Theme Will Support Upside As Investments Settle
Analysts have trimmed biote's average price target as firms reset expectations to a lower range of $2 to $5, citing the impact of a voluntary recall, higher operating investments, and slower clinic growth, even as they acknowledge progress on sales execution and systems upgrades. Analyst Commentary Recent research highlights a reset in expectations around biote, with lower price targets reflecting near term operational and growth headwinds, alongside recognition of execution progress and investments aimed at future expansion.내러티브 업데이트 • Mar 20
BTMD: Affordable Medicines Theme Will Support Upside As 2026 Plan Advances
Analysts have trimmed the consolidated price target for biote to a range of about $2 to $3. This reflects more cautious assumptions on growth and profitability following guidance tied to the voluntary recall, higher investment, and slower clinic expansion.내러티브 업데이트 • Mar 06
BTMD: Affordable Medicines Theme Will Drive Upside Despite Recent Cautious Reassessment
Analysts recently trimmed their 12 month price target on biote to $5 from $6, with the change tied to updated views on discount rates, revenue growth potential, profit margins, and a slightly higher assumed future P/E multiple, while still citing the broader affordable medicines theme as a key part of the thesis heading into 2026. Analyst Commentary Recent Street research has highlighted a more cautious tone around biote, with the 12 month price target trimmed to $5 from $6.내러티브 업데이트 • Feb 20
BTMD: Affordable Medicines Theme Will Support Upside Case Despite Lower Street Expectations
Analysts have trimmed their price target on biote to $5 from $6, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E. They continue to highlight the company’s fit within the broader affordable medicines theme.내러티브 업데이트 • Feb 05
BTMD: Affordable Medicines Theme Will Support Upside Potential Despite Lowered Expectations
Narrative update on biote Analysts have trimmed their price target on biote to US$5 from US$6, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions, while still highlighting affordable medicines as a supportive theme heading into 2026. Analyst Commentary Recent research reflects a more cautious stance on biote's share price while still pointing to the affordable medicines theme as an important support for the story heading into 2026.내러티브 업데이트 • Jan 22
BTMD: Affordable Medicines Theme Will Support Reassessed Outlook Into 2026
Analysts recently trimmed their price target on biote to $5 from $6, citing a mix of updated assumptions on fair value, discount rate, growth, margins, and future P/E expectations as they reassessed the stock within the broader affordable medicines theme heading into 2026. Analyst Commentary Recent Street research on Biote has focused on recalibrating expectations around valuation, execution, and growth, with some Bearish analysts taking a more cautious stance even as the broader affordable medicines theme remains in focus heading into 2026.내러티브 업데이트 • Jan 07
BTMD: Affordable Medicines Theme And Buybacks Will Support Upside Potential
Analysts have trimmed their price target on biote to $5 from $6, citing a still supportive view on the affordable medicines theme, even as they fine tune assumptions for revenue growth, margins, and future P/E expectations. Analyst Commentary Even with the trimmed price target, bullish analysts continue to frame biote within the affordable medicines theme, suggesting they still see room for the shares to reflect that positioning over time.내러티브 업데이트 • Dec 13
BTMD: Share Repurchases Will Support Future Upside In This Bullish Outlook
Analysts have modestly raised their price target on biote to reflect stronger expected revenue growth and a higher future earnings multiple, partially offset by more conservative margin and discount rate assumptions. What's in the News biote Corp.Seeking Alpha • Sep 10
Restructuring At Biote Will Drive Greater Growth And Profitability
Summary I maintain my Strong Buy rating on biote Corp. due to its promising growth prospects, despite ongoing restructuring and short-term earnings pressure. The company’s vertical integration, digital platform growth, and improved cost controls are driving margin expansion and long-term profitability potential. Restructuring aims to accelerate provider wins, deepen practitioner relationships, and boost financial discipline, though it has led to lower 2025 guidance. Valuation remains attractive with significant upside to intrinsic value, but investors should monitor debt levels, potential dilution, and execution risks. Read the full article on Seeking Alpha분석 기사 • Aug 09
Results: biote Corp. Exceeded Expectations And The Consensus Has Updated Its Estimates
One of the biggest stories of last week was how biote Corp. ( NASDAQ:BTMD ) shares plunged 26% in the week since its...내러티브 업데이트 • Aug 08
Commercial Reorganization And E-Commerce Expansion Will Drive Mixed Future Prospects
The significant drop in biote’s net profit margin combined with a sharply higher future P/E suggests deteriorating profitability and a less attractive valuation outlook, leading to the consensus analyst price target being revised down from $6.40 to $4.98. What's in the News Biote Corp.분석 기사 • Aug 08
Benign Growth For biote Corp. (NASDAQ:BTMD) Underpins Stock's 28% Plummet
NasdaqGM:BTMD 1 Year Share Price vs Fair Value Explore biote's Fair Values from the Community and select yours biote...분석 기사 • May 10
biote Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
biote Corp. ( NASDAQ:BTMD ) investors will be delighted, with the company turning in some strong numbers with its...분석 기사 • May 09
Market Participants Recognise biote Corp.'s (NASDAQ:BTMD) Earnings
With a price-to-earnings (or "P/E") ratio of 37.3x biote Corp. ( NASDAQ:BTMD ) may be sending very bearish signals at...분석 기사 • Dec 02
biote Corp. (NASDAQ:BTMD) Soars 26% But It's A Story Of Risk Vs Reward
biote Corp. ( NASDAQ:BTMD ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...분석 기사 • Sep 27
Market Cool On biote Corp.'s (NASDAQ:BTMD) Revenues
You may think that with a price-to-sales (or "P/S") ratio of 0.9x biote Corp. ( NASDAQ:BTMD ) is definitely a stock...
새 내러티브 • Sep 26
Biote's Innovative Strategies And Expansions Set To Enhance Revenue And Shareholder Value
Expanding the practitioner network and launching BioteRx aim to uniquely position the company in the wellness market, possibly boosting revenue through differentiated service offerings.Seeking Alpha • Sep 27
biote initiated as a buy at Truist on leadership in hormone optimization; sees 138% upside
Truist has initiated biote Corp. (NASDAQ:BTMD) with a buy rating highlighting the company's leadership in providing bioidentical hormone replacement therapy to improve hormonal imbalance. The firm has a $10 price target (~138% upside based on Monday's close). Analyst Gregory Fraser said that the company's platform "provides physicians with effective treatment options as well as a source of income" and added that the model has led to revenue and EBITDA growth. He noted that biote's (BTMD) growth strategy is focused on increasing utlilization of both existing and new partner clinics. Truist conducted a survey of 25 physicians who use biote's (BTMD) bioidentical hormone replacement therapy and found they expect to prescribe more of the company's pellet therapy over the next year. Seeking Alpha's Quant Rating views biote (BTMD) as a strong buy.Seeking Alpha • Sep 07
Biote partners with IMAC Holdings
biote Corp (NASDAQ:BTMD) said it had entered into a partnership with IMAC Holdings, to add the latter's services to its network of outpatient clinics that deliver orthopedic, regenerative, and advanced, non-surgical medical procedures. The Company said it had begun training IMAC medical professionals in the Biote Method for launching the treatments at select IMAC Regeneration Centers in September. "We are excited to add Biote’s services to IMAC clinics, which will be used to implement innovative weight loss and hormone optimization therapy within our current patient population," said Jeff Ervin, IMAC Founder and Chief Executive Officer. IMAC Holdings deliver sports medicine, orthopedic care, and restorative joint and tissue therapies for movement restricting pain and neurodegenerative diseases.주주 수익률
| BTMD | US Pharmaceuticals | US 시장 | |
|---|---|---|---|
| 7D | 3.3% | -1.9% | 2.2% |
| 1Y | -45.4% | 33.5% | 31.1% |
수익률 대 산업: BTMD은 지난 1년 동안 33.5%의 수익을 기록한 US Pharmaceuticals 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: BTMD은 지난 1년 동안 31.1%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| BTMD volatility | |
|---|---|
| BTMD Average Weekly Movement | 10.4% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: BTMD는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: BTMD의 주간 변동성(10%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2012 | 223 | Bret Christensen | www.biote.com |
는 호르몬 최적화 분야에서 실무 구축 사업을 운영하고 있습니다. 이 회사는 호르몬 불균형을 겪는 남성과 여성에게 생체 동일 호르몬 대체 펠렛 요법을 사용하여 호르몬 최적화에 대해 의사와 전문간호사를 교육합니다. 이 회사는 호르몬 최적화 분야의 의사를 위해 개발된 구성 요소로 구성된 종합적인 엔드투엔드 진료 구축 플랫폼인 Biote Method를 제공하며, Biote Method 교육, 훈련 및 인증, Biote 인증 의사가 호르몬 최적화 제품 재고를 주문, 추적 및 관리하고 기타 관리 요구 사항을 충족할 수 있는 진료 관리 소프트웨어, 주문 및 재고 관리를 용이하게 하는 재고 관리 소프트웨어, 사용 가능한 호르몬 대체 치료 제품에 관한 정보, 디지털 및 진료 시점 마케팅 지원 등을 제공합니다.
biote Corp. 기초 지표 요약
| BTMD 기초 통계 | |
|---|---|
| 시가총액 | US$81.24m |
| 순이익 (TTM) | US$15.60m |
| 매출 (TTM) | US$188.16m |
4.5x
주가수익비율(P/E)0.4x
주가매출비율(P/S)BTMD는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| BTMD 손익계산서 (TTM) | |
|---|---|
| 매출 | US$188.16m |
| 매출원가 | US$56.23m |
| 총이익 | US$131.93m |
| 기타 비용 | US$116.33m |
| 순이익 | US$15.60m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | 0.49 |
| 총이익률 | 70.12% |
| 순이익률 | 8.29% |
| 부채/자본 비율 | -220.4% |
BTMD의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/11 15:33 |
| 종가 | 2026/05/08 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
biote Corp.는 6명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Jeffrey Van Sinderen | B. Riley Securities, Inc. |
| Kaumil Gajrawala | Jefferies LLC |
| George Kelly | Roth Capital Partners |